Amid strong performance in the first half of 2023, Stada Arzneimittel’s private equity owners are considering a potential sale, though there are still no definite plans, according to CEO Peter Goldschmidt.
https://www.pharmalive.com/wp-content/uploads/2022/06/BioSoacehandshake6-14-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-08-16 09:01:462023-08-16 09:19:25Stada CEO confirms buyout rumors, sale could potentially fetch $11B
